Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
Status: Unknown
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• Age between 18 and 50 years at time of signing informed consent form.
• Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria.
• Full-field visual evoked potential (VEP) P100 latency in at least one eye of ≥118 ms.
• Kurtzke EDSS step 0.0 - 6.0.
• At the time of screening, being treated with a stable dose for at least 6 months of a category 1 multiple sclerosis DMT or for at least 2 years with a category 2 DMT.
Locations
Other Locations
Egypt
Nasser Institute for Research and Treatment
RECRUITING
Cairo
Contact Information
Primary
Mohamed Elsayed, master
mohamed.yosefelsayed@student.guc.edu.eg
+2001091282830
Time Frame
Start Date: 2022-02-01
Completion Date: 2023-03-28
Participants
Target number of participants: 80
Treatments
Experimental: Metformin (Cidophage®) and Interferon Beta 1 a (Rebiff ® 44mcg or Avonex ®)
Metformin 1000 mg (Cidophage® 1000 mg tablets, CID, Giza, Egypt) tablet twice daily for 6 months as add on therapy with Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®).
Active_comparator: Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
Interferon beta 1 a (Rebiff ® 44mcg or Avonex ®)
Related Therapeutic Areas
Sponsors
Leads: German University in Cairo